Literature DB >> 23874036

Community-acquired pneumonia: 2012 history, mythology, and science.

Gerald R Donowitz1.   

Abstract

Pneumonia remains one of the major disease entities practicing physicians must manage. It is a leading cause of infection-related morbidity and mortality in all age groups, and a leading cause of death in those older than 65 years of age. Despite its frequency and importance, clinical questions have remained in the therapy of community-acquired pneumonia including when to start antibiotics, when to stop them, who to treat, and what agents to use. Answers to these questions have involved historical practice, mythology, and science-sometimes good science, and sometimes better science. How clinical decisions are made for patients with community-acquired pneumonia serves as an illustrative model for other problem areas of medicine and allows for insight as to how clinical decisions have been made and clinical practice established.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23874036      PMCID: PMC3715915     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  25 in total

1.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Serum procalcitonin levels: comment on "Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in 'real life'".

Authors:  David Gilbert
Journal:  Arch Intern Med       Date:  2012-05-14

3.  Antibiotic timing and errors in diagnosing pneumonia.

Authors:  James A Welker; Michelle Huston; Jack D McCue
Journal:  Arch Intern Med       Date:  2008-02-25

Review 4.  Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia.

Authors:  Kenneth T Yu; Peter C Wyer
Journal:  Ann Emerg Med       Date:  2008-02-13       Impact factor: 5.721

5.  Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.

Authors:  J E Stahl; M Barza; J DesJardin; R Martin; M H Eckman
Journal:  Arch Intern Med       Date:  1999-11-22

6.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.

Authors:  D R Feikin; A Schuchat; M Kolczak; N L Barrett; L H Harrison; L Lefkowitz; A McGeer; M M Farley; D J Vugia; C Lexau; K R Stefonek; J E Patterson; J H Jorgensen
Journal:  Am J Public Health       Date:  2000-02       Impact factor: 9.308

7.  Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae.

Authors:  C C Koch; D J Esteban; A C Chin; M E Olson; R R Read; H Ceri; D W Morck; A G Buret
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

8.  Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL).

Authors:  Werner C Albrich; Frank Dusemund; Birgit Bucher; Stefan Meyer; Robert Thomann; Felix Kühn; Stefano Bassetti; Martin Sprenger; Esther Bachli; Thomas Sigrist; Martin Schwietert; Devendra Amin; Pierre Hausfater; Eric Carre; Jacques Gaillat; Philipp Schuetz; Katharina Regez; Rita Bossart; Ursula Schild; Beat Mueller
Journal:  Arch Intern Med       Date:  2012-05-14

9.  Emerging health care-associated infections in the geriatric population.

Authors:  L J Strausbaugh
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

Review 10.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

Authors:  Philipp Schuetz; Werner Albrich; Beat Mueller
Journal:  BMC Med       Date:  2011-09-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.